Kharituwe TB Contact Tracing Study

Hiv Clinical Trial

Official title:

Innovative Contact Tracing Strategies for Detecting TB in Mobile Rural and Urban South African Populations

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04520113
• Other study ID #: R01AI147681
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 1, 2020
• Est. completion date: June 2024

Study information

• Verified date: October 2023
• Source: Johns Hopkins Bloomberg School of Public Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the role of human mobility in fueling TB epidemics and estimate the potential impact of innovative case finding interventions tailored to mobile populations

Description:

The investigators propose a randomized trial of two novel TB case-finding interventions among household members of patients diagnosed with active TB: holiday-based screening in a rural South African province (Limpopo) and off-peak (weekend/evening) screening in an urban settlement into which many residents of Limpopo migrate for work. The investigators will enroll index cases of TB plus their household contacts in each setting and randomize them to novel versus standard contact investigation. In Specific Aim 1, investigators will use whole genome sequencing of all cases, overlaying transmission trees with data on human movement, to evaluate associations between mobility and TB transmission in this population. In Specific Aim 2, investigators will employ a multidisciplinary approach to compare novel versus standard contact investigation in each setting along the following dimensions: (a) effectiveness (number of secondary TB cases diagnosed and starting treatment); (b) implementation (reach, fidelity, and maintenance of contact investigation outside of business hours); (c) cost-effectiveness (cost per disability-adjusted life year) and budget impact; and (d) projected population-level impact on TB incidence. Successful completion of these aims will have long-term impact by characterizing the role of mobility in fueling TB epidemics and testing two tailored approaches to improve TB control in highly mobile populations - an underserved group that is increasingly recognized as playing a major role in global TB transmission.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15000
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 99 Years

Eligibility

TB index cases:

Inclusion criteria:

• Age 0-99 years (Including those recently deceased)

• Diagnosed with pulmonary TB at a study hospital or clinic (microbiological and/or chest x-ray diagnosis)

Exclusion criteria:

• Unwilling/unable to provide informed consent (including next of kin, for those recently deceased)

• Plan not to pursue TB treatment within the study district

• Unwilling/unable to comply with study procedures

Contacts:

Inclusion criteria:

• Age 0-99 years

• Currently resides with or visiting eligible TB index case

Exclusion Criteria:

• Unwilling/unable to provide informed consent

• Unwilling/unable to comply with study procedures

Related Conditions & MeSH terms

• Hiv
• Tuberculosis

Intervention

Behavioral:
• Household contact tracing
Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.

Locations

Country	Name	City	State
South Africa	Perinatal HIV Research Unit (PHRU)	Johannesburg
South Africa	Setshaba Research Centre	Soshanguve

Sponsors (3)

Lead Sponsor	Collaborator
Johns Hopkins Bloomberg School of Public Health	Perinatal HIV Research Unit of the University of the Witswatersrand, Setshaba Research Centre

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness: ratio of secondary TB identified and started on treatment per index case in novel strategy arm compared to standard contact investigation arm	The ratio of the number of secondary TB cases identified and started on treatment per index case in the novel strategy arm (off-peak screening in Soshanguve and holiday screening in Limpopo) compared to index cases receiving standard contact investigation.	Duration of study (30 months)
Secondary	The TB prevalence ratio, comparing highly mobile to less mobile index patients	The TB prevalence ratio, comparing highly mobile to less mobile individuals, measuring mobility on two scales (neighborhood/intra-urban and regional/intra-national). For the analysis: amount of time spent in transit, truncating long excursions at 50km (one hour).	Duration of study (30 months)
Secondary	TB strain relatedness using maximum likelihood transmission trees.	TB natural history, epidemiological, and whole genome sequencing (WGS)-derived phylogenetic data will be integrated into a statistical modeling framework to draw probabilistic conclusions about the likelihood of transmission between persons. "Transmitters" will be defined as individuals from whom at least one secondary case most likely originated.	Duration of study (30 months)
Secondary	Relative acceptability of each novel strategy compared to standard contact investigation	Relative acceptability of each novel strategy, compared against routine contact investigation. Acceptability of the intervention will be measured among index cases and contacts using a short questionnaire given to a randomly selected participant at a randomly selected 15% of the households visited. The interview will cover acceptability of the visit timing, notification, visit activities (TB screening, HIV testing) and study team interaction among others.	Duration of study (30 months)
Secondary	Feasibility of each strategy: proportion of potentially eligible index cases for whom a household visit was conducted	Feasibility of each strategy as the proportion of potentially eligible index cases for whom a household visit was conducted. All reasons why visits were unable to be conducted will be recorded (e.g. could not find household, no one ever home, visit not conducted during expected off-peak period).	Duration of study (30 months(
Secondary	Relative fidelity of each novel strategy compared to standard contact investigation	Relative fidelity of each novel strategy using a process checklist for each index case and household, including whether the household visit was offered and accepted, whether the visit was attempted, whether the visit was successful (i.e., enrolled at least one contact), whether symptom screening and sputum collection were completed and whether newly identified TB cases were notified and referred for treatment.	Duration of study (30 months)
Secondary	Sustainability of each novel strategy relative to standard contact tracing	Sustainability of each novel strategy by reporting the primary outcome and fidelity measures according to six-month time period over the course of the study.	Duration of study (30 months)
Secondary	Incremental cost-effectiveness ratio for each novel strategy relative to standard contact tracing	Defined as (cost of contact tracing strategy 2 - cost of strategy 1)/(effectiveness of strategy 2 - effectiveness of strategy 1), where effectiveness is modeled as the number of disability-adjusted life years (DALYs) averted by the intervention. The primary cost-effectiveness measures will be the incremental cost per DALY averted using novel strategies (holiday and off-hours contact tracing) compared to routine contact tracing in each setting separately.	Duration of study (30 months)